Cognitive Stimulation Therapy (CST) enhances the effects of Alzheimer’s disease medicine A key finding from the recently released 2nd systematic Cochrane review (Woods et al., 2023) is the confirmation that medication combined with CST results […]

Brain+ expands its first sales contract close to doubling it In December 2023 Brain+ closed its first sales contract with Herning Municipality, and Herning has chosen to expand that contract, nearly doubling the contractual size. […]

Respected dementia experts and Brain+ get EU grant to research how to optimize digital at-home treatments for people with dementia The EU Joint Programme – Neurodegenerative Disease Research has granted 496,000SEK (or 48,405 euros) to […]

New Cochrane review confirms the benefit and relevance of Cognitive Stimulation Therapy (CST) for people with dementia A 2nd systematic Cochrane review, ‘Cognitive stimulation to improve cognitive functioning in people with dementia’ (Woods et al., 2023), […]

Brain+ showcases its digital dementia products At the Danish-Japanese Welfare and Health Tech Business Conference Brain+ is part of a group of Danish welfare and health tech companies that have been invited to present their […]

Successful conclusion of EU project Alzheimer’s Detect & Prevent  with early validation of two Brain+ DTx technologies and extra funding  The information communicated in this announcement is “inside information” for the purposes of article 7 of […]

Brain+ completes Swedish research version of its dementia product with the Research Institutes of Sweden and extends the collaboration A strong Swedish partner research network Brain+ has over the last three years entered multiple Alzheimer’s […]

Results from a clinical study provide promising feasibility indications for Brain+’ CCT technology for cognitive training A study conducted by Nottingham University as part of the Brain+ led European Horizon2020 project called Alzheimer’s Detect & […]

Brain+ closes 2022 with the first municipal sale of its new dementia product and begins the monetization journey Another milestone has been met by Brain+ as it closes the year with the first sale of […]

3-year innovation project with the Danish Life Science Cluster is completed with the Brain+ CST-Therapist Companion product as the final output A 3-year collaboration project between VIA University College, MedTech Innovation Consortium (MTIC), and Brain+ […]

Brain+ announces Investor Webinar  following strong Q4 with product launch and succesful capital raise Brain+ invites you to an investor webinar after a strong quarter with commercial introduction of its first dementia product, a successful […]

Brain+ begins commercial pilot with volunteers from the DaneAge Association Brain+, a pioneer in the development of digital therapeutics for Alzheimer’s disease, is excited to announce the launch of a pilot project with DaneAge (Ældre Sagen) […]

Brain+ completes the implementation of an ISO 13485 Quality Management System for Medical Devices Brain+ has successfully completed the implementation of an ISO 13485-compliant Quality Management System (QMS). Such a system helps to set standards […]

A new WHO report points to Cognitive Stimulation Therapy (CST) and digital solutions As means to help solve the global dementia burden The World Health Organization (WHO) recently published a large report, A blueprint For Dementia […]

Brain+ adds new clinical and development competences To accelerate and support market access of its digital dementia product portfolio Rising star clinical dementia researcher to join the company in a new position as Clinical Director […]

Brain+ further advances its first digital dementia product, Cognitive Stimulation Therapy (CST) – Therapist Companion Commercial launch in Denmark will be November 1, 2022 Adaptation of a UK product version for the United Kingdom starts […]

Brain+ begins early activity and brand building in the US The United States (US) is a key future market for Brain+, and early brand building and exploration is now ongoing Brain+ has been selected and […]

Brain+ meets milestone with Rox Health (Roche Germany) Rox Health has approved the German version of Brain+’s first digital dementia product, CST-Therapist Companion, for commercial launch.  Meeting this milestone unlocks access for Brain+ to additional […]

New research report values Brain+ at DKK 4.1 per share in the base case, and DKK 6.4 in the bull case. The research report concludes that “Brain+ is in a strong position to grow towards […]

  Brain+ partners with German medical distributor Advances launch of its first CST dementia product in Germany to Q2 2023   Through Coopmed, Brain+ will be represented by experienced and local medical sales managers in […]